ASXL1 and myelodysplastic syndrome: This is concordant with previous reports demonstrating that RUNX1 and ASXL1 mutations contribute to the progression in lower-risk MDS, are more frequently mutated in rapidly progressing patients [11] and correlate with unfavorable outcome in MDS [12, 13].